Compare
Abvc Biopharma, Inc. vs Vyome Holdings, Inc vs Allarity Therapeutics, Inc. vs Provectus Biopharmaceuticals, Inc.
| Latest fiscal year | Abvc Biopharma, Inc. ABVC | Vyome Holdings, Inc HIND | Allarity Therapeutics, Inc. ALLR | Provectus Biopharmaceuticals, Inc. PVCT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $296.0K | $319.7K | $320.0K | $336.1K |
| Revenue growth (YoY) | -41.9% | +24.4% | n/a | -45.5% |
| Gross margin | n/a | 68.4% | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$7.91M | -$10.26M | -$11.23M | -$5.43M |
| EPS (Diluted) | -$0.39 | -$4.86 | n/a | -$0.01 |
| Operating cash flow | -$2.99M | -$3.75M | -$14.82M | -$3.33M |
| Free cash flow | n/a | n/a | -$14.83M | n/a |
| Cash & equivalents | $681.5K | $4.98M | $14.69M | $251.3K |
| Total assets | $21.06M | $6.50M | $18.26M | $697.5K |
| Total liabilities | $7.76M | $2.74M | $8.43M | $7.00M |
| Shareholders' equity | $11.11M | $3.76M | $9.83M | -$6.30M |
| Return on year-end equity | -71.2% | -272.8% | -114.3% | n/a |
| Shares outstanding | 25.05M | 5.92M | 16.08M | 420.28M |
Revenue, most recent five fiscal years
| Fiscal year | Abvc Biopharma, Inc. | Vyome Holdings, Inc | Allarity Therapeutics, Inc. | Provectus Biopharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $296.0K Ended 2025-12-31 | $319.7K Ended 2025-12-31 | $320.0K Ended 2025-12-31 | $336.1K Ended 2025-12-31 |
| 1 year earlier | $509.6K Ended 2024-12-31 | $256.9K Ended 2024-12-31 | $0 Ended 2024-12-31 | $617.1K Ended 2024-12-31 |
| 2 years earlier | n/a | $8.68M Ended 2023-12-31 | n/a | $557.7K Ended 2023-12-31 |
| 3 years earlier | n/a | $11.24M Ended 2022-12-31 | n/a | $989.0K Ended 2022-12-31 |
| 4 years earlier | n/a | $13.60M Ended 2021-12-31 | n/a | n/a |